Junning Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Junning Cao has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Dengju Li
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
49 shared publications - Fei Li
Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
49 shared publications - Hang Su
Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army General Hospital, Beijing, China
49 shared publications - Hanying Bao
Shanghai Yingli Pharmaceutical Co., Ltd., Shanghai, China. 11
49 shared publications - Hong Cen
Department of Medical Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China. 2
49 shared publications - Hui Zhou
23Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China
49 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 198
Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
- 5 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 198
Open AccessCorrection: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
- Open Access
- 1 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of these lesions are associated with aberrant BCR signaling, and prior studies in relapsed disease have suggested a degree of sensitivity to BTK inhibitors. These observations provided the rationale for evaluating zanubrutinib in the frontline setting for genomically defined high-risk disease. We conducted a prospective, single-center phase II study in previously untreated DLBCL patients aged 18-75 years with one or more of the above molecular features. To accommodate molecular testing time, patients received one initial cycle of R-CHOP, followed by five cycles of zanubrutinib plus R-CHOP (ZR-CHOP). Response was assessed using Lugano 2014 criteria. Primary endpoint is 3-year PFS; key secondary endpoints include ORR, OS, EFS, and safety. From February 2022 to April 2024, 59 patients were enrolled; 58 were evaluable for efficacy. Molecular subtyping identified 25 MCD-like, 16 A53-like, 3 N1-like, 10 other subtypes, and 4 MYC-rearranged cases. The ORR was 91.4% (53/58), with a CMR rate of 79.3% (46/58). MCD-like patients showed particularly favorable responses, with 84% achieving CMR. After a median follow-up of 30.1 months, the estimated 3-year PFS and OS were 80.3% (95%CI 70.5-91.5%) and 89.1% (95%CI 81.2-97.8%), respectively. MCD-like subgroup showed a 3-year OS of 100%, whereas N1-like had markedly poorer survival (2-year OS 33.3%). AEs occurred in 56/59 patients, mostly grade 1-2. Grade ≥ 3 events occurred in 57.6%, most commonly myelosuppression. No atrial fibrillation or other cardiac toxicities were observed. ZR-CHOP demonstrates encouraging activity and acceptable safety in molecularly selected high-risk DLBCL, particularly in the MCD-like subgroup. (ClinicalTrials.gov number, NCT05290337).
- 1 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessZanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of these lesions are associated with aberrant BCR signaling, and prior studies in relapsed disease have suggested a degree of sensitivity to BTK inhibitors. These observations provided the rationale for evaluating zanubrutinib in the frontline setting for genomically defined high-risk disease. We conducted a prospective, single-center phase II study in previously untreated DLBCL patients aged 18-75 years with one or more of the above molecular features. To accommodate molecular testing time, patients received one initial cycle of R-CHOP, followed by five cycles of zanubrutinib plus R-CHOP (ZR-CHOP). Response was assessed using Lugano 2014 criteria. Primary endpoint is 3-year PFS; key secondary endpoints include ORR, OS, EFS, and safety. From February 2022 to April 2024, 59 patients were enrolled; 58 were evaluable for efficacy. Molecular subtyping identified 25 MCD-like, 16 A53-like, 3 N1-like, 10 other subtypes, and 4 MYC-rearranged cases. The ORR was 91.4% (53/58), with a CMR rate of 79.3% (46/58). MCD-like patients showed particularly favorable responses, with 84% achieving CMR. After a median follow-up of 30.1 months, the estimated 3-year PFS and OS were 80.3% (95%CI 70.5-91.5%) and 89.1% (95%CI 81.2-97.8%), respectively. MCD-like subgroup showed a 3-year OS of 100%, whereas N1-like had markedly poorer survival (2-year OS 33.3%). AEs occurred in 56/59 patients, mostly grade 1-2. Grade ≥ 3 events occurred in 57.6%, most commonly myelosuppression. No atrial fibrillation or other cardiac toxicities were observed. ZR-CHOP demonstrates encouraging activity and acceptable safety in molecularly selected high-risk DLBCL, particularly in the MCD-like subgroup. (ClinicalTrials.gov number, NCT05290337).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
List of participating hospitals for the clinical trial NCT04370405
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
List of participating hospitals for the clinical trial NCT04370405
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Detailed inclusion and exclusion criteria for the clinical trial (NCT04370405)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Detailed inclusion and exclusion criteria for the clinical trial (NCT04370405)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Investigator-assessed response outcomes (FAS)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Investigator-assessed response outcomes (FAS)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Comparison of the concentrations of serum markers measured in patients with and without a response to linperlisib
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Comparison of the concentrations of serum markers measured in patients with and without a response to linperlisib
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Serum cytokine concentrations before and during treatment
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Serum cytokine concentrations before and during treatment